Bryan Urquhart
Medical · Fredericksburg, VANPI 1194867549
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $193,282 of the $263,781 with a category attached, or 73.3%. 26 manufacturers reported payments, led by Dexcom, Inc. at 52.7% of the total. Among medical clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $619.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$139K
- Novo Nordisk$98K
- AstraZeneca$8K
- Cequr Corporation$8K
- Sanofi-aventis U.S. LLC$5K
- Ascensia Diabetes Care US Inc.$3K
- plus $4K from 20 others
What the payments were for
- Consulting fees$38,90915%
- Speaking & faculty fees$193,28273%
- Travel & lodging$21,3138%
- Food & beverage$10,2774%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 176 | $138,908 |
| Novo Nordisk | 132 | $97,966 |
| AstraZeneca | 18 | $7,814 |
| Cequr Corporation | 5 | $7,543 |
| Sanofi-aventis U.S. LLC | 14 | $5,259 |
| Ascensia Diabetes Care US Inc. | 10 | $2,784 |
| Xeris Pharmaceuticals, Inc. | 3 | $1,035 |
| Acella Pharmaceuticals, LLC | 1 | $735 |
| Zealand Pharma US, Inc. | 23 | $374 |
| Corcept Therapeutics | 3 | $217 |
| Lilly USA, LLC | 9 | $212 |
| Abbott | 5 | $190 |
| Bayer | 3 | $181 |
| Amgen(2 entities) | 3 | $105 |
| Boehringer Ingelheim | 4 | $96 |
| Tandem Diabetes Care, Inc. | 3 | $57 |
| Novartis | 2 | $47 |
| Intuity Medical Inc | 2 | $39 |
| Insulet Corporation | 2 | $35 |
| Mannkind Corporation | 2 | $35 |
| Radius Health, Inc. | 1 | $34 |
| Kyowa Kirin, Inc. | 1 | $26 |
| IBSA Pharma Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Medtronic | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$82,124
- DEXCOM G7 GSS (161)$53,378
- RYBELSUS$30,652
- Ozempic$29,103
- DEXCOM STELO GLUCOSE BIOSENSOR$20,375
- Victoza$7,929
- CeQur Simplicity$7,510
- FARXIGA$6,560
- Tresiba$4,715
- EVERSENSE E3 SENSOR KIT - RETAIL$2,555
- SOLIQUA 100/33$1,547
- TOUJEO$1,428
- LOKELMA$1,000
- GVOKE PFS$987
- NP Thyroid 60$735
- Wegovy$250
- Korlym$189
- Kerendia$147
- FreeStyle Libre 2$125
How this compares
$263,781 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 204 | $396,030 |
| FarxigaDapagliflozin Propanediol | 96 | $111,362 |
| TrulicityDulaglutide | 36 | $72,040 |
| JardianceEmpagliflozin | 43 | $66,670 |
| Tresiba Flextouch U-100Insulin Degludec | 82 | $65,609 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $61,839 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $29,963 |
| Bydureon BciseExenatide Microspheres | 12 | $28,365 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $26,428 |
| TradjentaLinagliptin | 15 | $22,570 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $21,413 |
| Humalog Kwikpen U-100Insulin Lispro | 39 | $15,472 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $14,065 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $13,873 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $13,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $97,966 | $402,788219 claims |
| AstraZenecaFarxiga | $7,814 | $111,36296 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $96 | $110,65372 claims |
| Lilly USA, LLCTrulicity, Humalog | $212 | $83,88658 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $5,259 | $29,96328 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $22 | $4,317274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.
Other medical in Fredericksburg
- Sean BodinFredericksburg$8K
- Britanya FarleyFredericksburg$6K
- Margo BraggFredericksburg$6K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$42K
- Christine KesslerKing George$20K
- Janlyn AnthonyRichmond$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.